CO6910184A2 - Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide - Google Patents

Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide

Info

Publication number
CO6910184A2
CO6910184A2 CO12207243A CO12207243A CO6910184A2 CO 6910184 A2 CO6910184 A2 CO 6910184A2 CO 12207243 A CO12207243 A CO 12207243A CO 12207243 A CO12207243 A CO 12207243A CO 6910184 A2 CO6910184 A2 CO 6910184A2
Authority
CO
Colombia
Prior art keywords
amyloid
treatment
diseases associated
new compounds
proteins
Prior art date
Application number
CO12207243A
Other languages
English (en)
Inventor
Heiko Kroth
Cotinica Hamel
Pascal Benderitter
Wolfgang Froestl
Namapally Sreenivasachary
Andreas Muhs
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44246321&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6910184(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of CO6910184A2 publication Critical patent/CO6910184A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CO12207243A 2010-04-16 2012-11-15 Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide CO6910184A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160223 2010-04-16
EP10191616 2010-11-17

Publications (1)

Publication Number Publication Date
CO6910184A2 true CO6910184A2 (es) 2014-03-31

Family

ID=44246321

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12207243A CO6910184A2 (es) 2010-04-16 2012-11-15 Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide

Country Status (20)

Country Link
US (2) US9221812B2 (es)
EP (1) EP2558446B1 (es)
JP (1) JP5911470B2 (es)
KR (1) KR101851810B1 (es)
CN (1) CN102939282B (es)
AU (1) AU2011239966B2 (es)
BR (1) BR112012026249B1 (es)
CA (1) CA2794808C (es)
CL (1) CL2012002896A1 (es)
CO (1) CO6910184A2 (es)
DK (1) DK2558446T5 (es)
ES (1) ES2734552T3 (es)
IL (1) IL222268A (es)
MX (1) MX337548B (es)
MY (1) MY173699A (es)
NZ (1) NZ602777A (es)
RU (1) RU2603008C2 (es)
SG (1) SG184832A1 (es)
WO (1) WO2011128455A1 (es)
ZA (1) ZA201207613B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
CN104102839B (zh) * 2013-11-16 2017-10-27 西安电子科技大学 一种基于多尺度网格曲面形状特征的阿尔茨海默病脑皮层自动分类方法
CN104672208B (zh) * 2013-11-27 2017-01-04 中国科学院大连化学物理研究所 一种(3,5-双三氟甲基吡唑基)吡啶衍生物的合成方法
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
WO2015110263A1 (en) 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
IL301427A (en) 2014-02-25 2023-05-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic compounds for the treatment of complement-mediated disorders
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
CA2957898C (en) 2014-09-15 2023-02-21 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
JP6876625B2 (ja) * 2015-06-01 2021-05-26 リューゲン ホールディングス (ケイマン) リミテッド Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
CN108350053A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β表位及其抗体
KR20180088828A (ko) 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
KR20240036709A (ko) 2016-03-11 2024-03-20 에이씨 이뮨 에스에이 진단 및 치료를 위한 바이사이클릭 화합물
WO2018013867A1 (en) 2016-07-13 2018-01-18 Marineau Jason J Inhibitors of cyclin dependnt kinase 7 (cdk7)
WO2018067662A1 (en) * 2016-10-04 2018-04-12 University Of Miami Protein amyloidogenesis and related methods
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
RU2678987C2 (ru) 2017-04-28 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Пептид для лечения болезни альцгеймера
JP7330164B2 (ja) 2017-07-18 2023-08-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
US10633383B2 (en) 2018-01-05 2020-04-28 Ac Immune Sa Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
KR102477105B1 (ko) * 2018-01-05 2022-12-13 에이씨 이뮨 에스에이 알츠하이머병과 같은 타우 응집체와 연관된 장애의 치료, 완화 또는 예방을 위한 1,3,4,5-테트라히드로-2h-피리도[4,3-b]인돌 유도체
CA3088232A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics
CN108558905B (zh) * 2018-05-21 2021-03-12 华南农业大学 一种噻喃[4,3-b]吲哚类化合物及其制备方法和应用
TWI743484B (zh) 2018-06-04 2021-10-21 瑞士商Ac免疫公司 用於治療、改善或預防與tau聚集物相關之病症的新穎化合物
ES2924950T3 (es) * 2018-06-04 2022-10-11 Ac Immune Sa Novedosos compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados Tau
EA202091395A1 (ru) * 2018-06-04 2020-10-01 Ас Иммьюн Са ПРОИЗВОДНЫЕ 1,3,4,5-ТЕТРАГИДРО-2Н-ПИРИДО[4,3-b]ИНДОЛА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ, ТАКИХ КАК БОЛЕЗНЬ АЛЬЦГЕЙМЕРА
SG11202012150UA (en) 2018-06-08 2021-01-28 Ac Immune Sa Novel compounds for diagnosis
US20210165001A1 (en) * 2018-08-03 2021-06-03 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ, インコーポレーテッド 医学的障害の治療のための大環状化合物
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
EP3941477A1 (en) 2019-03-01 2022-01-26 AC Immune SA Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
WO2020247707A1 (en) * 2019-06-05 2020-12-10 Chunyu Wang SYSTEMS AND METHOD FOR INHIBITING γ-SECRETASE PRODUCTION OF AMYLOID-β PEPTIDES
CN110964035A (zh) * 2019-12-06 2020-04-07 北大医药股份有限公司 一种将奥氮平母液进行清洁回收的工业化方法
IL297965A (en) 2020-05-07 2023-01-01 Ac Immune Sa New compounds for diagnosis
WO2021252691A1 (en) * 2020-06-10 2021-12-16 Delix Therapeutics, Inc. Tricyclic psychoplastogens and uses thereof
MX2023003564A (es) 2020-09-30 2023-04-04 Astrazeneca Ab Compuestos y su uso en el tratamiento del cancer.
CA3223611A1 (en) * 2021-07-09 2023-01-12 Sironax Ltd. Ferroptosis modulators, preparations, and uses thereof
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
AU2022387830A1 (en) 2021-11-10 2024-05-23 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
WO2023083961A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
WO2023084000A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
WO2024020546A2 (en) * 2022-07-21 2024-01-25 Flexsys America L.P. Aminoindole antidegradant compounds and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
SE448153B (sv) * 1984-05-03 1987-01-26 Frans Gunnar Waldemar Fjelkner Klyv- eller kapklinga
EP0804584B2 (en) 1994-10-21 2008-07-09 Innogenetics N.V. Sequences of hepatitis c virus genotype 7 and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
JP2001506980A (ja) * 1996-11-19 2001-05-29 アムジエン・インコーポレーテツド アリールおよびヘテロアリール置換縮合ピロール抗炎症剤
JP4164201B2 (ja) * 1998-07-31 2008-10-15 キヤノン株式会社 電子写真装置
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
CA2482991A1 (en) 2002-04-19 2003-10-30 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004106307A2 (fr) * 2003-05-27 2004-12-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2005265270B2 (en) * 2004-06-22 2011-09-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
MX2007000092A (es) * 2004-06-30 2007-03-07 Vertex Pharma Azaindoles utiles como inhibidores de proteinas cinasas.
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
PL1893612T3 (pl) * 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
US20070073504A1 (en) 2005-09-26 2007-03-29 Bristol-Myers Squibb Company Configurable component handling device
JP2007099640A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
EP2808032B1 (en) 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
CA2668811A1 (en) * 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
ES2348208T3 (es) * 2006-12-07 2010-12-01 F. Hoffmann-La Roche Ag 2-aminoquinolinas como antagonistas de receptores 5-ht (5a).
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2008150799A1 (en) 2007-06-01 2008-12-11 Smithkline Beecham Corporation Imidazopyridine kinase inhibitors
BRPI0906799A2 (pt) 2008-01-11 2015-07-14 Hoffmann La Roche Moduladores para amiloide beta
EP2244709A4 (en) * 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
MX2010013192A (es) * 2008-06-16 2010-12-17 Hoffmann La Roche Monoamidas heteroaromaticas como antagonistas de receptor orexinina.
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
US8853391B2 (en) * 2008-12-18 2014-10-07 Merck Patent Gmbh Tricyclic azaindoles

Also Published As

Publication number Publication date
CN102939282A (zh) 2013-02-20
BR112012026249B1 (pt) 2021-08-17
BR112012026249A2 (pt) 2016-11-29
CA2794808C (en) 2019-08-20
DK2558446T5 (da) 2019-12-09
IL222268A (en) 2015-11-30
WO2011128455A1 (en) 2011-10-20
US20110280808A1 (en) 2011-11-17
MX2012011776A (es) 2012-12-17
CL2012002896A1 (es) 2013-08-09
SG184832A1 (en) 2012-11-29
CA2794808A1 (en) 2011-10-20
EP2558446B1 (en) 2019-06-12
EP2558446A1 (en) 2013-02-20
US9221812B2 (en) 2015-12-29
RU2012148713A (ru) 2014-05-27
KR101851810B1 (ko) 2018-04-26
US10500207B2 (en) 2019-12-10
AU2011239966A1 (en) 2012-10-25
JP2013525297A (ja) 2013-06-20
US20160158242A1 (en) 2016-06-09
NZ602777A (en) 2014-07-25
KR20130098154A (ko) 2013-09-04
ZA201207613B (en) 2018-12-19
CN102939282B (zh) 2015-12-02
IL222268A0 (en) 2012-12-31
ES2734552T3 (es) 2019-12-10
RU2603008C2 (ru) 2016-11-20
MY173699A (en) 2020-02-17
JP5911470B2 (ja) 2016-04-27
AU2011239966B2 (en) 2014-05-08
MX337548B (es) 2016-03-10
DK2558446T3 (da) 2019-08-26

Similar Documents

Publication Publication Date Title
CO6910184A2 (es) Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
CO6940432A2 (es) Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BR112013010157A2 (pt) inibidores do ibat para o tratamento de doenças do fígado
BR112014000033A2 (pt) compostos para o tratamento de dependência química
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
ES2547827T8 (es) Procedimiento para la purificación de la micafungina
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
BR112013030370A2 (pt) compostos de quinona para tratamento de doenças mediadas por ape1
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
SG11201403265VA (en) Medical composition for preventing or treating amyloid β peptide related diseases or conditions
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
BR112013033970A2 (pt) compostos e combinações farmacêuticas para o tratamento de doenças cerebrais isquêmicas e neurodegenerativas
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases

Legal Events

Date Code Title Description
FG Application granted